Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06518720
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-16
Brief Title:
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression TRANSCEND
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression TRANSCEND An Open-Label Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TRANSCEND
Brief Summary:
Psilocybin the chemical component of magic mushrooms has been administered with psychotherapy in several randomized clinical trials RCTs showing large and sustained antidepressant effects
The purpose of this study is to assess the feasibility tolerability and preliminary efficacy of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression
The purpose of this study is to assess the feasibility tolerability and preliminary efficacy of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None